<DOC>
	<DOC>NCT01674361</DOC>
	<brief_summary>This multi-center, randomized, double-blind, parallel-group, placebo-controlled study will evaluate the efficacy and safety of bitopertin (RO4917838) in combination with selective serotonin reuptake inhibitors (SSRI) in patients with obsessive-compulsive disorder. Patients will be randomized to receive either bitopertin 30 mg or bitopertin 10 mg or placebo orally daily in addition to their background therapy with an SSRI. Anticipated time on study treatment is 16 weeks.</brief_summary>
	<brief_title>A Study of Bitopertin (RO4917838) in Combination With Selective Serotonin Reuptake Inhibitors in Patients With Obsessive-Compulsive Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Compulsive Personality Disorder</mesh_term>
	<mesh_term>Obsessive-Compulsive Disorder</mesh_term>
	<mesh_term>Compulsive Behavior</mesh_term>
	<mesh_term>Serotonin</mesh_term>
	<mesh_term>Serotonin Uptake Inhibitors</mesh_term>
	<criteria>Adult patients, 18 to 65 years of age Primary diagnosis of obsessivecompulsive disorder (OCD) as per Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSMIVTR) On a stable dose of selective serotonin reuptake inhibitor (SSRI) for at least 8 weeks prior to screening an between screening and Day 1 An insufficient response to current treatment with an SSRI given at an adequate dose for at least 12 weeks prior to Day 1 Females who are not postmenopausal or surgically sterile must agree to use two adequate methods of contraception as defined by protocol from the start of screening until 90 days after the last dose of study drug Primary OCD symptom of hoarding More than two unsatisfactory trials within the last 2 years with different serotonin reuptake inhibitors (not including the current treatment with an SSRI) given in an adequate dose for at least 12 weeks Failure of more than one augmentation therapy or have had more than one augmentation therapy used in conjunction with an SSRI Recently initiated (within the last 6 months) or current behavioral therapy (cognitive behavioral therapy or exposure response prevention therapy) Any primary DSMIVTR Axis I disorder other than OCD Current or prior history of bipolar disorder, schizophrenia or other psychotic disorders, schizoaffective disorder, autism or autistic spectrum disorders, borderline personality disorder, or Gilles de la Tourette syndrome Any eating disorder within the last 6 months History od substance dependence and/or substance abuse in the last 6 months, with the exception of nicotine Previous treatment with bitopertin or another GlyT1 inhibitor Positive urine drug screening for cannabis, amphetamines (including MDMA/ecstasy), cocaine, barbiturate, and/or opiates Prior or current general medical condition that may impair cognition or other neuropsychiatric functioning Body mass index &lt;18.5 kg/m2 or &gt;40 kg/m2 Pregnant or lactating women</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2013</verification_date>
</DOC>